1. Hong Kong Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
China Traditional Chinese Medicine Holdings Co. Limited

China Traditional Chinese Medicine Holdings Co. Limited

CHIZF
China Traditional Chinese Medicine Holdings Co. LimitedUS flagOther OTC
0.22
USD
- -
- -
1.10BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
Revenue per Share
0.68
1.05
1.01
1.47
1.88
2.33
2.84
2.94
3.78
2.84
3.6
3.28
2.93
Basic EPS, GAAP
0.1
0.16
0.17
0.22
0.26
0.3
0.32
0.33
0.38
0.15
0.26
0.01
-0.07
Free Cash Flow per Basic Share
- -
0.09
0.08
0.27
0.14
-0.01
0.08
-0.2
-0.02
0.11
0.14
0.41
0.39
Dividend per Share
- -
- -
- -
0.06
0.07
0.1
0.1
0.04
0.05
0.06
0.05
- -
0.08
Book Value per Share
0.11
1
3
2.61
2.21
3.16
3.24
2.38
2.38
3.88
4.07
4.08
3.93
Tangible Book Value per Share
0.32
0.44
0.57
0.57
0.82
1.52
1.8
2.19
2.56
2.7
2.98
3.14
3.18
Basic Weighted Avg Shares
2,051
2,534
3,687
4,450
4,432
4,822
5,036
5,036
5,036
5,036
5,036
5,036
5,036
Sales/Revenue/Turnover
1,395
2,650
3,709
6,533
8,338
11,259
14,321
14,806
19,053
14,304
18,122
16,510
14,745
Operating Margin (%)
18.37
20.86
17.56
20.96
20.7
17.8
17.32
16.74
14.2
8.32
7.5
5.6
4.21
Depreciation Expense
68
119
162
337
423
510
591
684
850
1,099
1,133
1,130
1,159
Net Income, GAAP
198
413
626
967
1,170
1,439
1,588
1,663
1,933
764
1,285
54
-342
Effective Tax Rate (%)
16.09
14.39
17.28
16.66
16.32
15.6
17.7
16.57
15.75
14.18
- -
87.27
- -
Profit Margin (%)
14.23
15.59
16.87
14.8
14.04
12.78
11.09
11.23
10.14
5.34
7.09
0.33
-2.32
Working Capital
514
961
2,393
4,564
6,689
5,853
4,177
7,597
9,439
7,864
10,467
11,039
9,975
LT Debt
668
671
850
2,909
4,515
2,225
262
2,542
2,893
529
2,191
1,892
260
Total Equity
2,835
3,257
12,140
12,756
13,815
17,511
19,051
20,896
22,662
22,948
23,937
23,933
23,028
Return on Invested Capital (%)
7.97
11.03
5.6
7.21
8.01
7.84
8.33
8.04
8.42
3.65
- -
0.41
- -
Return on Capital (%)
20.94
17.5
7.27
5.82
7.35
7.85
6.9
7.49
9.64
4.21
- -
0.41
- -
Return on Common Equity (%)
96.65
29.75
9.2
8.53
10.93
11.49
10.06
11.75
16.13
4.85
6.42
0.26
-1.7

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
6.89%
2.05%
-3.78%
Free Cash Flow
-151.89%
-133.78%
-5.53%
Net Income, GAAP
-69.09%
-160.92%
-732.68%
Sales/Revenue/Turnover
18.02%
2.17%
-10.69%
Total Cash Common Dividend
- -
- -
65.19%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
18,122
2024
- -
- -
- -
- -
16,510
2025
- -
- -
- -
- -
14,745

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.26
2024
- -
- -
- -
- -
0.01
2025
- -
- -
- -
- -
-0.07

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.05
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
0.08

Company Description

APIChat
CEO
Jun Yang
Full Time Employees
16,753
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Address
Emperor Group Centre Wan Chai Hong Kong
IPO Date
Nov 1, 2021
Website
china-tcm.com.cn
Similar Companies
Delivra Health Brands Inc. (DHB.V)
HempAmericana, Inc (HMPQ)
Yuyu Pharma, Inc. (000225.KS)
Elixxer Ltd. (ELIXF)
Zhuhai Rundu Pharmaceutical Co., Ltd. (002923.SZ)
Haemato AG (HAEK.DE)
Business
China Traditional Chinese Medicine Holdings Co. Limited, a subsidiary of China National Pharmaceutical Group Co. Ltd., operates as an investment holding company engaged in the research, development, production, and sale of traditional Chinese medicine (TCM) and pharmaceutical products primarily in the People's Republic of China, Hong Kong, and internationally. The company manufactures and sells concentrated TCM granules, TCM decoction pieces, TCM healthcare products, and TCM finished drugs under brands including Yi Fang, Tian Jiang, Tong Ji Tang, Medi-World, De Zhong, and Feng Liao Xing; it also produces and operates Chinese medicinal herbs, TCM great health products, and TCM clinics, while providing Chinese medical consultation, diagnosis, TCM physiotherapy, prescription services with concentrated TCM granules, medical herbs trading, pharmaceutical product trading, TCM marketing, advertising, consulting, and property leasing. It serves hospitals, retail pharmacies, and offline medical institutions through four main segments: Yi Fang, Tian Jiang, Tong Ji Tang, and Medi-World. Founded in 1955 with roots tracing to historic brands like Tongjitang established in 1573, the company maintains its headquarters and management center in Foshan, Guangdong province, and was formerly known as China Traditional Chinese Medicine Co. Limited before changing its name in 2016. In recent developments, China Traditional Chinese Medicine Holdings renews key continuing connected transactions with Sinopharm Group, including the Financial Services Agreement, Master Purchase Agreement, and Master Supply Agreement effective through 2028 to support financial services, material procurement, and product sales; it also faces a privatization proposal from a Sinopharm-led consortium offering HKD 4.6 per share for the remaining stake, following an unsuccessful 2021 attempt.